Cerus Corporation (CERS)
- Previous Close
1.6800 - Open
1.6800 - Bid 1.6300 x 300
- Ask 1.6900 x 200
- Day's Range
1.6500 - 1.7007 - 52 Week Range
1.2100 - 3.0800 - Volume
579,742 - Avg. Volume
1,607,619 - Market Cap (intraday)
304.555M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.30
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
www.cerus.comRecent News: CERS
Performance Overview: CERS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERS
Valuation Measures
Market Cap
300.93M
Enterprise Value
331.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.91
Price/Book (mrq)
5.72
Enterprise Value/Revenue
2.12
Enterprise Value/EBITDA
-12.57
Financial Highlights
Profitability and Income Statement
Profit Margin
-23.97%
Return on Assets (ttm)
-7.91%
Return on Equity (ttm)
-61.71%
Revenue (ttm)
156.37M
Net Income Avi to Common (ttm)
-37.49M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
65.85M
Total Debt/Equity (mrq)
179.62%
Levered Free Cash Flow (ttm)
-27.75M